A

AstraZeneca

Global pharmaceutical company developing prescription medicines

Personal Assistant

Full-TimeDeadline 12/31/26
No salary listed
Mid
Shanghai, China
In Person
Administrative & Executive AssistanceExecutive Support

About the job

Requirements
  • Prior experience as a Personal Assistant.
  • Ability to adhere to established processes.
  • Specialist knowledge of administrative and business support activities within the relevant area.
  • Competence in using relevant office equipment and systems.
  • Experience with a variety of software and systems.
  • Comprehensive understanding of the local organization and its business processes, including their interfaces with other relevant processes and information systems.
  • Ability to perform the mathematical calculations and activities relevant to the role.
  • Ability to design and maintain efficient systems for personal and team use.
Responsibilities
  • Respond on behalf of the Vice President to different stakeholders, maintaining professionalism and addressing conflicting priorities.
  • Handle complex or escalated inquiries from other Personal Assistants or secretarial staff.
  • Manage Senior Managers' email accounts to schedule appointments and respond to or redirect routine inquiries from internal and external sources.
  • Transcribe, type, format, and proofread correspondence, invoices, contracts, meeting minutes, reports, speeches, and presentations using word processing, presentation, graphics, and spreadsheet software, in the local language and English as required.
  • Use desktop publishing software to create complex documents that support departmental activities.
  • Provide specialized, project-based administrative support as required.
  • Coordinate internal and external meetings or conferences, including scheduling, arranging attendee travel, and organizing necessary amenities.
  • Execute additional administrative tasks with independent judgment and discretion.
  • Prepare and distribute documents, presentation materials, and official information releases to relevant stakeholders.
  • Coach and mentor less experienced secretarial help desk staff to help them resolve problems.
  • Plan, organize, and schedule personal workload using system tools to ensure timely and accurate completion of all activities.
Desired Qualifications
  • Relevant vocational qualifications or equivalent experience.
  • Team management skills.

About the company

AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Get referred to AstraZeneca

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Massachusetts expansion adds nearly 2,000 scientists and expands workforce over 50% by 2026.
  • H1 2026 revenue rose 6% to $30.7 billion, driven by oncology growth.
  • FLAURA2 and CLARITY-Gastric01 strengthened Tagrisso and sonesitatug vedotin in 2026.

What critics are saying

  • Farxiga faced US and Japan generic competition, plus China VBP, in H1 2026.
  • Forxiga patent fights continue in France, Poland, Portugal, and Australia through 2027.
  • Tagrisso dependence stays acute; one patent loss or trial failure would crush growth.

What makes AstraZeneca unique

  • Pascal Soriot doubled down on oncology, opening Cambridge R&D center October 5, 2026.
  • AstraZeneca's ADC and bispecific platform drove the $2 billion Summit Therapeutics deal September 28, 2026.
  • Tagrisso, Imfinzi, and rare disease franchises keep AstraZeneca diversified across high-value therapeutic categories.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Holidays
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

6%

1 year growth

8%

2 year growth

8%
Yahoo Finance
Nov 1st, 2026
AstraZeneca launches $2B restructuring to fund pipeline as revenue rises 7%

AstraZeneca said total revenue rose 7% and core earnings per share grew 14% in the first nine months of 2026, as oncology and rare disease products offset patent expiries on key cardiovascular drugs. The company reported on its third-quarter call on October 30, 2026. It launched a three-year programme, Reshaping for Sustainable Growth, to deliver $1.5 billion in annual pre-tax savings. The plan carries up to $2 billion in one-off costs, and the savings will go into research on cell therapies and weight management. AstraZeneca also formed a partnership with Summit Therapeutics to combine antibody-drug conjugates with next-generation immuno-oncology treatments. Lung cancer drug Tagrisso brought in $2.1 billion in quarterly sales. Chief executive officer Pascal Soriot expects more than 20 major trial readouts and said the company is "firmly on track to deliver our 2030 ambition.

Yahoo Finance
Oct 30th, 2026
AstraZeneca shares jump 7% as cancer drugs lift Q3 revenue to $16.21B and $1.5B savings plan

AstraZeneca shares rose nearly 7% on Friday after the drugmaker beat earnings forecasts and announced a cost-cutting plan. Investors increasingly believe its cancer drugs can replace revenue lost to cheaper generic rivals. Third-quarter revenue rose 7% to $16.21 billion. Core earnings were $2.79 per share, against $2.59 expected. Oncology revenue jumped 17%, with Enhertu sales up 35% and Imfinzi up 26%. The company plans to save $1.5 billion a year, mainly to fund research, though restructuring could cost up to $2 billion upfront. Sales of diabetes and heart drug Farxiga fell 25% amid generic competition. Chief executive officer Pascal Soriot said AstraZeneca is on track for its 2030 goal of $80 billion in annual revenue.

Yahoo Finance
Oct 30th, 2026
AstraZeneca shares jump 7.65% as it plans $2B restructuring to unlock $1.5B in annual savings

AstraZeneca shares rose 7.65% to $187.75 at 12:40 ET on October 30, after the drugmaker announced a restructuring with one-time costs of up to $2 billion. The plan targets $1.5 billion in annualised pretax benefits. AstraZeneca will reinvest the savings, mainly in its development pipeline. Third-quarter revenue reached $16.21 billion, up 7% at constant currencies. Full-year guidance was unchanged. At the targeted savings, the maximum restructuring bill equals about 1.3 years of gross savings. That figure excludes reinvestment and timing of implementation, so the earnings benefit depends on when savings arrive and how quickly the company spends them.

Yahoo Finance
Oct 30th, 2026
AstraZeneca Q3 revenue rises 6.7% to $16.21B, beating estimates as EPS hits $2.79

AstraZeneca reported third-quarter revenue of $16.21 billion, up 6.7% from a year earlier. That beat the Zacks Consensus Estimate of $16.09 billion by 0.71%. Earnings per share rose to $2.79 from $2.38 a year ago, topping the $2.60 consensus by 7.31%. Cancer drug Tagrisso brought in $2.09 billion worldwide, up 12% and above the $1.98 billion estimate. Fasenra sales rose 13.6% to $602 million. Brilinta fell 48.6% to $75 million, and worldwide Symbicort sales dropped 10.2% to $666 million. Shares have gained 10.6% over the past month, against 0.7% for the Zacks S&P 500 composite.

Yahoo Finance
Oct 30th, 2026
AstraZeneca CEO eyes $20B+ from 2027 trial readouts as Q3 beats and $1.5B savings plan unveiled

AstraZeneca chief executive officer Pascal Soriot said the company's 2027 drug trial readouts could generate more than $20 billion in peak annual sales. The company has more than 180 projects in development, including treatments for cancer, respiratory illnesses, and rare diseases. Third-quarter revenue rose 7% to $16.21 billion, beating estimates of about $16 billion. Core earnings per share increased 17% to $2.79, against expectations of $2.59. Oncology revenue jumped 17% to $7.77 billion, while diabetes drug Farxiga sales fell 25% to $1.61 billion amid generic competition. AstraZeneca also announced a restructuring programme targeting $1.5 billion in annual savings by 2029, with up to $2 billion in one-time costs. Shares rose about 5% in pre-market trading.